Matinas BioPharma receives NYSE American trading halt due to low price; plans 1-for-50 reverse split

Matinas BioPharma Holdings, Inc.

Trading of MTNB common stock halted by NYSE American on August 27, 2024 due to low trading price.
Halt to remain until reverse stock split (1-for-50) is consummated; split effective 5:00 PM EST on August 30, 2024.
Split-adjusted trading expected to begin September 3, 2024, subject to NYSE American approval.
If post-split price does not meet Section 1003(f)(v) requirements, NYSE could suspend trading and delist shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.